185 related articles for article (PubMed ID: 38089670)
1. Seroconversion and safety of Covid-19 vaccines in pa-tients with chronic liver disease and liver transplant: A systematic review.
Elzouki AY; Elshafei MN; Aziz A; Elzouki I; Waheed MA; Farooqui K; Azad AM; Habas E; Danjuma MI
Qatar Med J; 2023; 2023(3):21. PubMed ID: 38089670
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis.
Cheung KS; Mok CH; Mao X; Zhang R; Hung IF; Seto WK; Yuen MF
Clin Mol Hepatol; 2022 Oct; 28(4):890-911. PubMed ID: 36263669
[TBL] [Abstract][Full Text] [Related]
3. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
Thuluvath PJ; Robarts P; Chauhan M
J Hepatol; 2021 Dec; 75(6):1434-1439. PubMed ID: 34454993
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
Lee ARYB; Wong SY; Chai LYA; Lee SC; Lee MX; Muthiah MD; Tay SH; Teo CB; Tan BKJ; Chan YH; Sundar R; Soon YY
BMJ; 2022 Mar; 376():e068632. PubMed ID: 35236664
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of COVID-19 vaccines in chronic liver disease patients and liver transplant recipients: A systematic review and meta-analysis.
Luo D; Chen X; Du J; Mei B; Wang A; Kuang F; Fang C; Gan Y; Peng F; Yang X; Dahmen U; Li B; Song S
Liver Int; 2023 Jan; 43(1):34-48. PubMed ID: 35986903
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing immunogenicity and safety of SARS-CoV-2 vaccine in liver transplantation recipients: a systematic review and meta-analysis.
Luo X; Lessomo FYN; Yu Z; Xie Y
Front Immunol; 2023; 14():1145081. PubMed ID: 37731498
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccine immune response in patients with plasma cell dyscrasia: a systematic review.
Faizan U; Nair LG; Bou Zerdan M; Jaberi-Douraki M; Anwer F; Raza S
Ther Adv Vaccines Immunother; 2023; 11():25151355231190497. PubMed ID: 37645011
[TBL] [Abstract][Full Text] [Related]
10. Seroconversion After Coronavirus Disease 2019 Vaccination in Patients Awaiting Liver Transplantation: Fact or Fancy?
Calleri A; Saracco M; Pittaluga F; Cavallo R; Romagnoli R; Martini S
Liver Transpl; 2022 Feb; 28(2):180-187. PubMed ID: 34564945
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
[TBL] [Abstract][Full Text] [Related]
12. A prospective observational cohort study of covid-19 epidemiology and vaccine seroconversion in South Western Sydney, Australia, during the 2021-2022 pandemic period.
Potter D; Diep J; Munro C; Lin N; Xu R; Wong J; Porritt R; Maley M; Foo H; Makris A
BMC Nephrol; 2024 Apr; 25(1):131. PubMed ID: 38609846
[TBL] [Abstract][Full Text] [Related]
13. Use of COVID-19 vaccines in patients with liver disease and post-liver transplantation: Position statement of the Saudi association for the study of liver diseases and transplantation.
Alqahtani SA; Barry M; Memish Z; Hashim A; Alfares MA; Alghamdi SA; Al-Hamoudi WK; Al-Judaibi B; Alhazzani W; Al-Tawfiq JA; Abaalkhail F
Saudi J Gastroenterol; 2021; 27(4):201-207. PubMed ID: 34100388
[TBL] [Abstract][Full Text] [Related]
14. Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis.
Verleye A; Wijtvliet V; Abrams S; Hellemans R; Bougrea R; Massart A; Pipeleers L; Wissing KM; Ariën KK; De Winter BY; Van Damme P; Abramowicz D; Ledeganck KJ
Nephrol Dial Transplant; 2022 Jul; 37(8):1566-1575. PubMed ID: 35544087
[TBL] [Abstract][Full Text] [Related]
15. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients.
Arslan M; Wiesner RH; Poterucha JJ; Zein NN
Transplantation; 2001 Jul; 72(2):272-6. PubMed ID: 11477352
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of the efficacy and safety of intradermal versus intramuscular hepatitis B vaccination in end-stage renal disease population unresponsive to primary vaccination series.
Yousaf F; Gandham S; Galler M; Spinowitz B; Charytan C
Ren Fail; 2015 Aug; 37(7):1080-8. PubMed ID: 26258528
[TBL] [Abstract][Full Text] [Related]
19. Side Effects Associated With Homologous and Heterologous COVID-19 Vaccines: A Cross-Sectional Study in Saudi Arabia.
Mohammed RA; Yazbik RS; Baajajah LH; Alharthy SF; Alsalahi H; Mahjaa MA; Barakat MM; Badawy MI; Sultan I
Cureus; 2023 Jan; 15(1):e34030. PubMed ID: 36814743
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
